CASSAVA SCIENCES INC SAVA 深 滬
已收盤 08-08 16:00:00 美东时间
2.18
-0.010
-0.46%
華盛通- 最 高2.24
- 今 開2.23
- 成交量 55.93万股
- 最 低 2.14
- 昨 收 2.19
- 總市值 1.05亿
- 52周最高 33.98
- 市盈率 靜 --
- 換手率 1.16%
- 52周最低 1.15
- 委 比 -7.65%
- 總股本 4830.79万
- 歷史最高 146.16
- 量 比 0.60
- 振 幅 4.57%
- 歷史最低 1.00
- 每 手 1
- 風險率 11.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ginkgo Bioworks files $500M mixed securities shelf
Ginkgo Bioworks (NYSE:DNA) filed a prospectus for the offer and sale of $500M mixed securities shelf. This preliminary prospectus is not an offer to sell these securities. Filing More on Ginkgo Bi...
08-08 05:59
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
Cassava Sciences, Inc. has appointed Dr. Joseph Hulihan as Chief Medical Officer. With over 25 years of experience in developing therapies for epilepsy and other neurological disorders, Dr. Hulihan will focus on advancing simufilam, a potential treatment for Tuberous Sclerosis Complex (TSC)-related epilepsy. The clinical study for simufilam is expected to begin in H1 2026. Dr. Hulihan previously served as CMO at Marinus Pharmaceuticals and held s...
08-07 11:30
Cassava Sciences Reports Preclinical Results Of A Study Evaluating Simufilam In A Well-accepted Mouse Model Of Tuberous Sclerosis Complex (TSC)-related Epilepsy, First Clinical Study For Simufilam In TSC-related Epilepsy Expected To Begin In H1 2026
The Tsc1-CKO mice were treated with several doses of simufilam. Seizure activity was monitored for approximately three weeks after onset, and simufilam was evaluated against treatment with vehicle alone. The
08-04 19:33
SELLAS gains as mid-stage trial for leukemia drug succeeds
SELLAS Life Sciences (NASDAQ:SLS) traded higher in the premarket on Tuesday after the New York-based biotech said that a Phase 2 trial that tested its antitumor agent SLS009 (tambiciclib) as part of a...
07-15 20:22
CEL-SCI announces pricing of $5.7 million offering
CEL-SCI (NYSE:CVM) announced on Friday the pricing of a best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock is being sold at an offering price of $3.82 per share,...
07-12 03:04
Agenus unit, MiNK surges after peer-reviewed data for lead drug
Shares of MiNK Therapeutics (NASDAQ:INKT) climbed over 500% in the morning hours on Friday after the nano-cap cell therapy developer, which is a unit of Agenus (NASDAQ:AGEN), announced peer-reviewed d...
07-11 23:12
Silicom Secures First Design Win With U.S. Edge Networking Provider For Custom Edge Device; Targeting ~$1M Annual Run Rate With Multi-Million-Dollar Scale-Up Potential By 2026
- $1 million annual run rate with potential for a significant multi-million-dollar scale-up -KFAR SAVA, Israel, July 7, 2025 /PRNewswire/ -- Silicom Ltd. (NASDAQ:SILC), a leading provider of networking and data
07-07 20:33
INOVIO announces pricing of $25M public offering
INOVIO Pharmaceuticals (NASDAQ:INO) on Thursday priced an underwritten public offering of 14.29 million shares of its common stock, along with accompanying Series A and Series B warrants to purchase u...
07-03 19:57
Cassava Sciences Presented A Poster At The TSC International Research Conference
The poster detailed two important observations that support Cassava's plan to initiate human clinical studies in H1 2026 to evaluate simufilam as a treatment for Tuberous Sclerosis Complex (TSC)-related
06-30 19:02
Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting
Cassava Sciences announced plans to initiate human clinical studies in H1 2026 to evaluate simufilam for TSC-related epilepsy. Preclinical mouse model data showed simufilam reduced seizure frequency by 60%, while Phase 3 safety data from 1,929 Alzheimer's patients demonstrated a favorable safety profile.
06-30 11:00
